

Amendments to the Claims

1-17. (Cancelled)

18. (Currently amended) A method of inhibiting treating a mammal suffering from cerebral embolism-induced cerebrovascular hyperpermeability which comprises administering an effective injecting an amount of a hepatocyte growth factor to a into a cerebral ventricle of the mammal which amount is sufficient to ameliorate a symptom associated with embolism-induced disorder.

19-24. (Cancelled)

25. (Currently amended) The method according to claim 18, wherein the symptom is a decline in learning function, and the method results in an improvement in the a decline in learning function is improved.

26. (Currently amended) The method according to claim 18, wherein the symptom is a decline in memory function, and the method results in an improvement in the a decline in memory function is improved.

27. (Currently amended) The method according to claim 18, wherein the symptom is dementia, and the method results in an improvement in the dementia is improved.

28. (New) The method according to claim 18, wherein the mammal has a cerebral edema.